IL327564A - Use of a phosphodiesterase 10 inhibitor to treat Tourette syndrome - Google Patents

Use of a phosphodiesterase 10 inhibitor to treat Tourette syndrome

Info

Publication number
IL327564A
IL327564A IL327564A IL32756426A IL327564A IL 327564 A IL327564 A IL 327564A IL 327564 A IL327564 A IL 327564A IL 32756426 A IL32756426 A IL 32756426A IL 327564 A IL327564 A IL 327564A
Authority
IL
Israel
Prior art keywords
capsule
crystalline solid
solid
amount
compound
Prior art date
Application number
IL327564A
Other languages
English (en)
Hebrew (he)
Original Assignee
Noema Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Noema Pharma Ag filed Critical Noema Pharma Ag
Publication of IL327564A publication Critical patent/IL327564A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychology (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
IL327564A 2020-06-05 2021-06-04 Use of a phosphodiesterase 10 inhibitor to treat Tourette syndrome IL327564A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063035310P 2020-06-05 2020-06-05
US202163160302P 2021-03-12 2021-03-12
PCT/EP2021/065074 WO2021245280A1 (en) 2020-06-05 2021-06-04 Use of a phosphodiesterase 10 inhibitor for the treatment of tourette syndrome

Publications (1)

Publication Number Publication Date
IL327564A true IL327564A (en) 2026-05-01

Family

ID=76325557

Family Applications (2)

Application Number Title Priority Date Filing Date
IL327564A IL327564A (en) 2020-06-05 2021-06-04 Use of a phosphodiesterase 10 inhibitor to treat Tourette syndrome
IL298713A IL298713B1 (en) 2020-06-05 2021-06-04 Use of a phosphodiesterase 10 inhibitor to treat Tourette syndrome

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL298713A IL298713B1 (en) 2020-06-05 2021-06-04 Use of a phosphodiesterase 10 inhibitor to treat Tourette syndrome

Country Status (13)

Country Link
US (2) US11883385B2 (enExample)
EP (1) EP4161526A1 (enExample)
JP (2) JP7748974B2 (enExample)
KR (2) KR20250171459A (enExample)
CN (2) CN121891333A (enExample)
AU (1) AU2021285225B2 (enExample)
BR (1) BR112022024751A2 (enExample)
CA (1) CA3180793A1 (enExample)
CL (2) CL2022003400A1 (enExample)
IL (2) IL327564A (enExample)
MX (1) MX2022015400A (enExample)
PH (1) PH12023550007A1 (enExample)
WO (1) WO2021245280A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12544364B2 (en) * 2020-06-05 2026-02-10 Noema Pharma Ag Use of a phosphodiesterase 10 inhibitor for the treatment of tourette syndrome
JP2024505515A (ja) * 2021-01-28 2024-02-06 ノエマ ファーマ アクツィエンゲゼルシャフト 小児期発症流暢症の治療のための方法
WO2026068583A1 (en) * 2024-09-25 2026-04-02 Noema Pharma Ag Use of phosphodiesterase 10 inhibitor gemlapodect for weight loss

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5605897A (en) * 1991-04-23 1997-02-25 Eli Lilly And Company 2-methyl-thieno-benzodiazepine
US20030032579A1 (en) * 2001-04-20 2003-02-13 Pfizer Inc. Therapeutic use of selective PDE10 inhibitors
EP1723134A2 (en) * 2004-02-18 2006-11-22 Pfizer Products Incorporated Tetrahydroisoquinolinyl derivatives of quinazoline and isoquinoline
US7786139B2 (en) * 2006-11-21 2010-08-31 Omeros Corporation PDE10 inhibitors and related compositions and methods
US8349824B2 (en) 2010-12-07 2013-01-08 Hoffmann-La Roche Inc. Triazolopyridine compounds
CA2845578C (en) * 2011-08-25 2016-02-16 Merck Sharp & Dohme Corp. Pyrimidine pde10 inhibitors
EP4616915A3 (en) * 2012-07-12 2025-12-17 Emalex Biosciences, Inc. Ecopipam for treatment of tourettes syndrome
TR201904614T4 (en) * 2013-02-27 2019-05-21 Mochida Pharm Co Ltd Novel pyrazole derivative.
CN105164126B (zh) * 2013-04-30 2017-05-31 豪夫迈·罗氏有限公司 吡唑酰胺的Pd‑催化偶联

Also Published As

Publication number Publication date
KR20230040978A (ko) 2023-03-23
US11883385B2 (en) 2024-01-30
KR20250171459A (ko) 2025-12-08
CL2022003400A1 (es) 2023-07-28
CA3180793A1 (en) 2021-12-09
EP4161526A1 (en) 2023-04-12
WO2021245280A9 (en) 2022-01-27
WO2021245280A1 (en) 2021-12-09
CN116137811A (zh) 2023-05-19
BR112022024751A2 (pt) 2023-03-07
MX2022015400A (es) 2023-03-16
US20230149372A1 (en) 2023-05-18
IL298713B1 (en) 2026-05-01
IL298713A (en) 2023-02-01
JP2025183391A (ja) 2025-12-16
PH12023550007A1 (en) 2024-03-11
JP7748974B2 (ja) 2025-10-03
JP2023528896A (ja) 2023-07-06
CN121891333A (zh) 2026-04-21
KR102892626B1 (ko) 2025-11-28
CN116137811B (zh) 2026-01-09
CL2025002636A1 (es) 2025-11-28
AU2021285225A1 (en) 2023-01-19
AU2021285225B2 (en) 2026-06-04
US20260076950A1 (en) 2026-03-19

Similar Documents

Publication Publication Date Title
IL282270A (en) An Aurora A kinase inhibitor for use in the treatment of neuroblastoma
IL298713B1 (en) Use of a phosphodiesterase 10 inhibitor to treat Tourette syndrome
PL3919491T3 (pl) Inhibitor akt
IL308476A (en) Inhibitors of the menin-mil interaction
GB202008201D0 (en) Inhibitor compounds
PL4153597T3 (pl) Związki hamujące kinazę zależną od cykliny do leczenia zaburzeń medycznych
IL253521A0 (en) Combinations of a phosphoinositide 3-kinase inhibitor compound and a cdk4/6 inhibitor compound for cancer treatment
IL312171A (en) Innovative use of the quinazolinone compound for cancer treatment
GB202416046D0 (en) Compounds of use in methods for the treatment or prohylaxis of a coronavirus infection or covid 19
IL312650A (en) CDK4 inhibitor for cancer treatment
IL284856A (en) DBAIT molecule in combination with a kinase inhibitor for cancer treatment
PL4021269T3 (pl) Poduszka czyszcząca do przetwarzania powierzchni
IL316829A (en) Menin-MLL inhibitors for cancer treatment
GB202004960D0 (en) Inhibitor compounds
GB202110373D0 (en) Inhibitor compounds
IL312885A (en) Nitroxoline for use in the treatment or prevention of flexiform neurofibroma
IL292596A (en) Use of Janus kinase inhibitor and telomerase inhibitor to treat myeloproliferative tumor
GB201918404D0 (en) Compounds and their use for the treatment of aplha1-antitrypsin deficiency
IL309172A (en) Vulbanazine for use in the additional treatment of schizophrenia
IL297684B1 (en) Processes for preparing a kinase inhibitor
HK40092019A (en) Use of a phosphodiesterase 10 inhibitor for the treatment of tourette syndrome
GB202117224D0 (en) Inhibitor compounds
ZA202109826B (en) Nk1 inhibitors for the treatment of malaria
GB202012969D0 (en) Inhibitor compounds
PL4146225T3 (pl) Związki metylotioniniowe do zastosowania w leczeniu hipoksemii